Wed, Apr 16, 2025
Volume 18, Issue 4 (Jul-Aug 2024)
mljgoums 2024, 18(4): 8-10 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Faris Hasan Z, Şay Coşkun U S. Antibiotic resistance profile of Acinetobacter baumannii isolates identified from blood cultures. mljgoums 2024; 18 (4) :8-10
URL: http://mlj.goums.ac.ir/article-1-1692-en.html
URL: http://mlj.goums.ac.ir/article-1-1692-en.html
1- Instutite of Graduate Studies, Tokat Gaziosmanpaşa University, Tokat, Turkey
2- Department of Medical Microbiology, Faculty of Medicine, Tokat Gaziosmanpaşa University, Tokat, Turkey ,umut.saycoskun@gop.edu.tr
2- Department of Medical Microbiology, Faculty of Medicine, Tokat Gaziosmanpaşa University, Tokat, Turkey ,
Abstract: (864 Views)
Background: Acinetobacter baumannii (A. baumannii) has emerged as the predominant etiological agent responsible for bloodstream infections among hospitalized patients. The objective of this study was to evaluate antibiotic resistance in A. baumannii isolates identified from blood cultures.
Methods: A retrospective cohort evaluation was conducted on 117 A. baumannii isolates obtained from blood cultures collected between 2018 and 2019 at the Microbiology Laboratory of Tokat Gaziosmanpaşa University Hospital (Türkiye). The blood culture samples were incubated using the BACT-ALERT 3D system (bioMérieux, Durham, NC, USA). Microorganism identification and antibiotic susceptibility testing were performed using the VITEK 2 (bioMérieux, France) automated system.
Results: Of the 117 samples, 59.8% were obtained from males and 40.2% from females. A total of 90.6% of blood culture samples were collected from the intensive care unit, and 88.9% of isolates were identified as multidrug-resistant (MDR). The highest resistance was observed against meropenem (99.1%), while the lowest resistance was noted for colistin (17.1%) and tigecycline (27.3%). Resistance to amikacin was 74.4%, while resistance levels to gentamicin, tobramycin, cefoxitin, and cefotaxime were within the range of 80–90%. Resistance to imipenem, amoxicillin/clavulanic acid, ampicillin/sulbactam, ceftazidime, cefepime, ciprofloxacin, levofloxacin, meropenem, and ertapenem exceeded 90%.
Conclusion: The increasing number of MDR A. baumannii isolates poses a significant threat to all hospitalized patients. However, colistin and tigecycline remain preferable options for the treatment of MDR A. baumannii infections. Considering the increasing prevalence of MDR A. baumannii isolates, periodic analysis of epidemiological data in healthcare centers is important for managing resistance to colistin and tigecycline.
Methods: A retrospective cohort evaluation was conducted on 117 A. baumannii isolates obtained from blood cultures collected between 2018 and 2019 at the Microbiology Laboratory of Tokat Gaziosmanpaşa University Hospital (Türkiye). The blood culture samples were incubated using the BACT-ALERT 3D system (bioMérieux, Durham, NC, USA). Microorganism identification and antibiotic susceptibility testing were performed using the VITEK 2 (bioMérieux, France) automated system.
Results: Of the 117 samples, 59.8% were obtained from males and 40.2% from females. A total of 90.6% of blood culture samples were collected from the intensive care unit, and 88.9% of isolates were identified as multidrug-resistant (MDR). The highest resistance was observed against meropenem (99.1%), while the lowest resistance was noted for colistin (17.1%) and tigecycline (27.3%). Resistance to amikacin was 74.4%, while resistance levels to gentamicin, tobramycin, cefoxitin, and cefotaxime were within the range of 80–90%. Resistance to imipenem, amoxicillin/clavulanic acid, ampicillin/sulbactam, ceftazidime, cefepime, ciprofloxacin, levofloxacin, meropenem, and ertapenem exceeded 90%.
Conclusion: The increasing number of MDR A. baumannii isolates poses a significant threat to all hospitalized patients. However, colistin and tigecycline remain preferable options for the treatment of MDR A. baumannii infections. Considering the increasing prevalence of MDR A. baumannii isolates, periodic analysis of epidemiological data in healthcare centers is important for managing resistance to colistin and tigecycline.
Research Article: Research Article |
Subject:
Microbiology
Received: 2023/07/13 | Accepted: 2023/11/26 | Published: 2025/03/11 | ePublished: 2025/03/11
Received: 2023/07/13 | Accepted: 2023/11/26 | Published: 2025/03/11 | ePublished: 2025/03/11
References
1. Harding CM, Kinsella RL, Palmer LD, Skaar EP, Feldman MF. Medically Relevant Acinetobacter Species Require a Type II Secretion System and Specific Membrane-Associated Chaperones for the Export of Multiple Substrates and Full Virulence. PLoS Pathog. 2016; 12(1): e1005391. [View at Publisher] [DOI] [PMID] [Google Scholar]
2. Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges. Clin Microbiol Rev. 2017; 30(1): 409-447. [View at Publisher] [DOI] [PMID] [Google Scholar]
3. WHO. Antimicrobial resistance surveillance in Europe 2023 - 2021 data. Stockholm: European Centre for Disease Prevention and Control and World Health Organization; 2023. [View at Publisher]
4. Snyder JW. Blood cultures: The importance of meeting pre-analytical requirements in reducing contamination, optimizing sensitivity of detection, and clinical relevance. Clin Microbiol Newsl. 2015; 37(7): 53-7. [View at Publisher] [DOI] [Google Scholar]
5. Baba S K, Jan A, Lone M S, Kakru D K, Fomda B A, Bashir G, et al . Early Detection of Antibiotic Resistance in Positive Blood Cultures: A Study from a Tertiary Care Center in India. Med Lab J. 2023; 17(3): 8-14. [View at Publisher] [DOI] [Google Scholar]
6. Jang TN, Lee SH, Huang CH, Lee CL, Chen WY. Risk factors and impact of nosocomial Acinetobacter baumannii bloodstream infections in the adult intensive care unit: a case-control study. J Hosp Infect. 2009; 73(2): 143-50. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Breakpoints tables for interpretation of MICs and zone diameters. EUCAST documents version 8.1. European Committee on Antimicrobial Susceptibility Testing, 2018. [View at Publisher]
8. Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and non-central lineassociated Bloodstream Infection). Device-associated Module, BSI. Centers for Disease Control and Prevention, CDC. January 2019. [View at Publisher]
9. Tabah A, Buetti N, Staiquly Q, Ruckly S, Akova M, Aslan AT, et al. EUROBACT-2 Study Group, ESICM, ESCMID ESGCIP and the OUTCOMEREA Network. Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study. Intensive Care Med. 2023; 49(2): 178-190. [View at Publisher] [DOI] [PMID] [Google Scholar]
10. Dobrović K, Škrobo T, Selec K, Jelić M, Čivljak R, Peršec J, et al. Healthcare-Associated Bloodstream Infections Due to Multidrug-Resistant Acinetobacter baumannii in COVID-19 Intensive Care Unit: A Single-Center Retrospective Study. Microorganisms. 2023; 11(3): 774. [View at Publisher] [DOI] [PMID] [Google Scholar]
11. Alcántar-Curiel MD, Huerta-Cedeño M, Jarillo-Quijada MD, Gayosso-Vázquez C, Fernández-Vázquez JL, Hernández-Medel ML, et al. Gram-negative ESKAPE bacteria bloodstream infections in patients during the COVID-19 pandemic. PeerJ. 2023; 11: e15007. [View at Publisher] [DOI] [PMID] [Google Scholar]
12. Tacconelli E, Sifakis F, Harbarth S, Schrijver R, van Mourik M, Voss A, et al. Surveillance for control of antimicrobial resistance. Lancet Infect Dis. 2018; 18(3): e99-e106. [View at Publisher] [DOI] [PMID] [Google Scholar]
13. Xie R, Zhang XD, Zhao Q, Peng B, Zheng J. Analysis of global prevalence of antibiotic resistance in Acinetobacter baumannii infections disclosed a faster increase in OECD countries. Emerg Microbes Infect. 2018; 7(1): 31. [View at Publisher] [DOI] [PMID] [Google Scholar]
14. Mączyńska B, Jama-Kmiecik A, Sarowska J, Woronowicz K, Choroszy-Król I, Piątek D, et al. Changes in Antibiotic Resistance of Acinetobacter baumannii and Pseudomonas aeruginosa Clinical Isolates in a Multi-Profile Hospital in Years 2017-2022 in Wroclaw, Poland. J Clin Med. 2023; 12(15): 5020. [View at Publisher] [DOI] [PMID] [Google Scholar]
15. Bagherian F, Nikoonejad A, Allami A, Dodangeh S, Yassen L T, Hosienbeigi B. Investigation of Antibiotic Resistance Pattern in Isolated From Urine and Blood Samples of Patients Admitted To the Intensive Care Unit of Velayat Hospital in Qazvin, Iran. Med Lab J. 2021;15(6):31-37. [View at Publisher] [DOI] [Google Scholar]
16. Al-Tamimi M, Albalawi H, Alkhawaldeh M, Alazzam A, Ramadan H, Altalalwah M, et al. Multidrug-Resistant Acinetobacter baumannii in Jordan. Microorganisms. 2022 ;10(5): 849. [View at Publisher] [DOI] [PMID] [Google Scholar]
17. Jalali Y, Liptáková A, Jalali M, Payer J. Moving toward Extensively Drug-Resistant: Four-Year Antimicrobial Resistance Trends of Acinetobacter baumannii from the Largest Department of Internal Medicine in Slovakia. Antibiotics. 2023; 12(7): 1200. [View at Publisher] [DOI] [PMID] [Google Scholar]
18. Mohammed MA, Ahmed MT, Anwer BE, Aboshanab KM, Aboulwafa MM. Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones. PLoS One. 2020; 15(8): e0238195. [View at Publisher] [DOI] [PMID] [Google Scholar]
19. Castilho SRA, Godoy CSM, Guilarde AO, Cardoso JL, André MCP, Junqueira-Kipnis AP, et al. Acinetobacter baumannii strains isolated from patients in intensive care units in Goiânia, Brazil: Molecular and drug susceptibility profiles. PLoS One. 2017; 12(5): e0176790. [View at Publisher] [DOI] [PMID] [Google Scholar]
20. Tewari R, Chopra D, Wazahat R, Dhingra S, Dudeja M. Antimicrobial Susceptibility Patterns of an Emerging Multidrug Resistant Nosocomial Pathogen: Acinetobacter baumannii. Malays J Med Sci. 2018; 25(3): 129-134. [View at Publisher] [DOI] [PMID] [Google Scholar]
21. Tafreshi N, Babaeekhou L, Ghane M. Antibiotic resistance pattern of Acinetobacter baumannii from burns patients: increase in prevalence of blaOXA-24-like and blaOXA-58-like genes. Iran J Microbiol. 2019; 11(6): 502-509. [View at Publisher] [DOI] [PMID] [Google Scholar]
22. Seleim SM, Mostafa MS, Ouda NH, Shash RY. The role of pmrCAB genes in colistin-resistant Acinetobacter baumannii. Sci Rep. 2022; 12(1): 20951. [View at Publisher] [DOI] [PMID] [Google Scholar]
23. Farajnia S, Lotfi F, Dehnad A, Shojaie M, Raisi R, Rahbarnia L, et al. The molecular characterization of colistin-resistant isolates of Acinetobacter baumannii from patients at intensive care units. Iran J Microbiol. 2022; 14(3): 319-327. [View at Publisher] [DOI] [PMID] [Google Scholar]
24. Perovic O, Duse A, Chibabhai V, Black M, Said M, Prentice E, et al.; for GERMS-SA. Acinetobacter baumannii complex, national laboratory-based surveillance in South Africa, 2017 to 2019. PLoS One. 2022; 17(8): e0271355. [View at Publisher] [DOI] [PMID] [Google Scholar]
25. Heydarlou MM, Durmaz G, Ibrahi M BMS. Evaluation of sulbactam and colistin/sulbactam efficacy against multiple resistant Acinetobacter baumannii blood isolates. Indian J Med Microbiol. 2022; 40(4): 567-571. [View at Publisher] [DOI] [PMID] [Google Scholar]
26. Poirel L, Jayol A, Nordmanna P. Polymyxins: Antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin Microbiol Rev. 2017; 30(2): 557-96. [View at Publisher] [DOI] [PMID] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Enamad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.